Industry and government stakeholders outlined a push to reduce the timeline required to file investigational drug applications, targeting pre-IND work as a major source of unnecessary delay. The effort, branded around “Back to School 2026,” focuses on clarifying and streamlining the data sponsors must generate before IND submission. The proposal is positioned as an efficiency “low-hanging fruit” within first-in-human trial launches, with attention on reducing sponsor pre-work while aligning expectations around what constitutes acceptable pre-IND evidence. The reforms are being framed as part of broader attempts to address uneven US versus global competition in early clinical development. For biotech developers, the changes would affect how internal scientific teams and CRO partners plan preclinical packages, trial readiness milestones, and timelines tied to early-stage studies. The reporting also highlights that FDA and other agencies, Congress, biopharma, and academic groups are converging on incremental reforms rather than a single structural overhaul.